NICE has backed Celgene’s multiple myeloma pill Imnovid in combination with dexamethasone for use on the NHS in new draft guidance. Imnovid has been given approval for the treatment of people with relapsed or refractory multiple myeloma that have already undergone three previous treatments, including Celgene’s Revlimid and Takeda’s Velcade. The U-turn by the UK
The Welsh government has recommended Celgene’s Abraxane to treat pancreatic cancer on the National Health Service (NHS) in Wales. Specifically, Abraxane (nab-paclitaxel) has been approved by the All Wales Medicines Strategy Group as an option for use in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Mark
The Scottish Medicines Consortium (SMC) has approved Celgene’s Vidaza (azacitidine) in patients with advanced myelodysplastic syndromes (MDS). The SMC’s decision takes into account benefits of a new patient access scheme for Vidaza, which is the only drug available in Europe for advanced myelodysplastic syndrome, a rare but debilitating disease which affects around 2,150 people in
